| scholarly article | Q13442814 |
| P50 | author | JoAnn E. Manson | Q6204013 |
| Susan D. Reed | Q114942444 | ||
| P2093 | author name string | C Chen | |
| B V Howard | |||
| J Wactawski-Wende | |||
| R Haque | |||
| R T Chlebowski | |||
| T E Rohan | |||
| C A Thomson | |||
| G L Anderson | |||
| G E Sarto | |||
| C D Runowicz | |||
| A K Aragaki | |||
| M S Simon | |||
| P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| Estrogen carcinogenesis in breast cancer | Q28292500 | ||
| Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens | Q28320364 | ||
| Long-term postmenopausal hormone therapy and endometrial cancer | Q33650188 | ||
| Progesterone: the ultimate endometrial tumor suppressor. | Q33773307 | ||
| The 2012 Hormone Therapy Position Statement of The North American Menopause Society | Q34161400 | ||
| Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial | Q34208463 | ||
| Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations | Q34287536 | ||
| National use of postmenopausal hormone therapy: annual trends and response to recent evidence | Q34288307 | ||
| Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects | Q34317537 | ||
| Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. | Q34321877 | ||
| Menopausal hormone therapy and risk of endometrial cancer | Q34345110 | ||
| Endometrial cancer and hormone-replacement therapy in the Million Women Study | Q34415404 | ||
| Symptom experience after discontinuing use of estrogen plus progestin | Q34433581 | ||
| The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer | Q34555256 | ||
| Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study | Q34576753 | ||
| Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status | Q34581334 | ||
| The decrease in breast-cancer incidence in 2003 in the United States | Q34620356 | ||
| Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin | Q34758422 | ||
| Breast cancer after use of estrogen plus progestin in postmenopausal women | Q34938322 | ||
| Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis | Q35002418 | ||
| Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer | Q35510465 | ||
| The Epidemiology of Endometrial and Ovarian Cancer | Q35676052 | ||
| Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls | Q35886066 | ||
| Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial | Q36143058 | ||
| Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? | Q36189328 | ||
| Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial | Q36851595 | ||
| Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer | Q36929282 | ||
| Type I and II endometrial cancers: have they different risk factors? | Q36977055 | ||
| Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? | Q37277121 | ||
| Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. | Q37442687 | ||
| Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women | Q37480990 | ||
| Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials | Q37658616 | ||
| Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer | Q37661580 | ||
| Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries | Q37923626 | ||
| Global consensus statement on menopausal hormone therapy. | Q38089075 | ||
| Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative | Q39367613 | ||
| Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. | Q40879219 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). | Q42679385 | ||
| Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition | Q42852626 | ||
| Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition | Q43520576 | ||
| Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. | Q43781057 | ||
| Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial | Q44602959 | ||
| Association of Exogenous Estrogen and Endometrial Carcinoma | Q46021645 | ||
| Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer | Q46427223 | ||
| The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial | Q50617188 | ||
| Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins | Q50970377 | ||
| Recent changes in endometrial cancer trends among menopausal-age US women | Q51212025 | ||
| Case-control study of postmenopausal hormone replacement therapy and endometrial cancer | Q52930339 | ||
| Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-Analysis | Q56525963 | ||
| Implementation of the women's health initiative study design | Q57055364 | ||
| Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial | Q70918505 | ||
| Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast | Q73276429 | ||
| Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women | Q80394797 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| endometrial cancer | Q944777 | ||
| P577 | publication date | 2015-12-14 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial | |
| P478 | volume | 108 |
| Q58804285 | A study of the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer |
| Q64891209 | Cancer Progress and Priorities: Uterine Cancer. |
| Q92500366 | Chronic Exposure of Mice to Bisphenol-A Alters Uterine Fibroblast Growth Factor Signaling and Leads to Aberrant Epithelial Proliferation |
| Q59805381 | Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis |
| Q52579984 | Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis |
| Q91909252 | Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database |
| Q92795160 | Estrogen Enhances Endometrial Cancer Cells Proliferation by Upregulation of Prohibitin |
| Q60728526 | Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women |
| Q57689276 | Hormone replacement therapy for women previously treated for endometrial cancer |
| Q48516369 | Hormone therapy as a management strategy for lung metastasis after 5 years of endometrial cancer: A case report and literature review |
| Q38975101 | Hormone-replacement therapy: current thinking |
| Q64108528 | Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors |
| Q38976756 | Intentional Weight Loss and Endometrial Cancer Risk |
| Q58592781 | Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors o |
| Q30238978 | Long-term hormone therapy for perimenopausal and postmenopausal women |
| Q28077183 | Major clinical research advances in gynecologic cancer in 2015 |
| Q40045531 | Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials |
| Q38700757 | Safety and benefit considerations for menopausal hormone therapy |
| Q42229710 | Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. |
Search more.